Home Carboxes 1000413-72-8
1000413-72-8,MFCD18251445
Catalog No.:AA0000JU

1000413-72-8 | [(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
≥95%
in stock  
$112.00   $78.00
- +
5mg
98%
in stock  
$156.00   $109.00
- +
25mg
98%
in stock  
$192.00   $134.00
- +
50mg
98%
in stock  
$350.00   $245.00
- +
100mg
98%
in stock  
$462.00   $323.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0000JU
Chemical Name:
[(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid
CAS Number:
1000413-72-8
Molecular Formula:
C29H32O7S
Molecular Weight:
524.6252
MDL Number:
MFCD18251445
SMILES:
OC(=O)C[C@@H]1COc2c1ccc(c2)OCc1cccc(c1)c1c(C)cc(cc1C)OCCCS(=O)(=O)C
Properties
Computed Properties
 
Complexity:
828  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
37  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
11  
XLogP3:
4.7  

Literature

Title: Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Journal: Toxicological sciences : an official journal of the Society of Toxicology 20180601

Title: Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury.

Journal: Toxicological sciences : an official journal of the Society of Toxicology 20170501

Title: Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.

Journal: Journal of medicinal chemistry 20160526

Title: Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.

Journal: Diabetes, obesity & metabolism 20150701

Title: High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.

Journal: Nature 20140904

Title: A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.

Journal: PloS one 20130101

Title: Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.

Journal: Journal of clinical pharmacology 20120701

Title: A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.

Journal: Clinical pharmacology and therapeutics 20120701

Title: Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.

Journal: Journal of medicinal chemistry 20120426

Title: Could FFAR1 assist insulin secretion in type 2 diabetes?

Journal: Lancet (London, England) 20120414

Title: TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England) 20120414

Title: GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism 20120301

Title: The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.

Journal: The Journal of pharmacology and experimental therapeutics 20120201

Title: Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.

Journal: Journal of medicinal chemistry 20111013

Title: TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.

Journal: The Journal of pharmacology and experimental therapeutics 20111001

Title: Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.

Journal: ACS medicinal chemistry letters 20100909

Title: Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

Journal: Nature 20030313

Title: Tsujihata Y,et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.J Pharmacol Exp

Title: Yoshiyuki Tsujihata, et al. TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. JPET July 13, 2011

Title: Nagatake T, et al. 17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. J Allergy Clin Immunol. 2017 Dec 26. pii: S0091-6749(17)32949-4.

Title: Urano Y, et al. Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. Chem Biol Interact. 2018 Sep 20;296:185-197.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1000413-72-8
Tags:1000413-72-8 Molecular Formula|1000413-72-8 MDL|1000413-72-8 SMILES|1000413-72-8 [(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid